J K Cements Ltd
JKCEMENTJ K Cements Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
The sharpest disagreement: annual EPS moved +15.3% against a −18.5% price move — the market has not yet caught up with the delivery.
The price is in a downtrend (31 weeks in) while the P/E sits at the 70th percentile of its own 10-year range. Underneath, the last four quarters read deteriorating — profit −15.1% year on year, and 218% of the last 3 years' profit arrived as cash. What settles it: whether the price catches up with earnings that have already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
J K Cements Ltd trades at ₹5,444, in a downtrend and 31 weeks into that stage. That is −1.4% against its own 200-day average. It sits at 30% of a 52-week range of ₹4,815 to ₹6,947. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 2 straight weeks.
Today the stock is in a downtrend — week 31 of stage 4, confirmed. At ₹5,444 it trades −1.4% versus its 200-day average and sits at 30% of its 52-week range (₹4,815–₹6,947).
Against the market, two honest reads. Cumulative: over the last 10.4 years the stock moved +833% while the NIFTY 500 moved +276% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 2 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
J K Cements Ltd trades at 43.1× P/E, at the pricey end of its own range (70th percentile). Its long-run median P/E is 36.6×, measured across 10.4 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 43.1× is at the pricey end of its own range (70th percentile), against a long-run median of 36.6× measured over 10.4 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved +15.3% against a −18.5% price move — earnings outran the price, pushing the multiple DOWN its own range.
The price move, decomposed: over 5y, of the +10.8%/yr price move, ~+5.7%/yr came from earnings growth and ~+5.1 pp from the multiple (expanding); over 10y, of the +22.5%/yr price move, ~+31.4%/yr came from earnings growth and ~−8.9 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: Mixed Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
J K Cements Ltd reads as mixed on its fundamental arc. Mixed — no clean majority across the growth curves, ROCE slipping at 13.4% — the per-curve reads carry the story. The read is built from 12 quarters across 4 curves, on full evidence.
Why it matters: when the curves disagree, the per-curve reads above matter more than any single verdict.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +15.5% | +12.2% | +15.7% | +12.1% |
| Profit | +13.3% | +33.4% | +7.0% | +33.5% |
| EPS | +15.3% | +32.8% | +6.9% | +31.6% |
| Share price | −18.5% | +18.7% | +10.8% | +22.5% |
4-Factor Sector Score
48.1/100 — rank 12 of 26 in Cement · 94% evidence confidence
J K Cements Ltd scores 48.1 out of 100 against the 26 companies it is compared with in Cement, ranking 12. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 11.2 + 16.4 + 8.1 + 12.4 = 48.1. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
J K Cements Ltd reported ₹4,032 Cr of revenue in the Jun 26 quarter, +20.3% year on year. That is the 6th straight quarter of year-on-year growth. Over 10 years it has compounded at 12.1% a year. The last full year, FY26, came in at ₹13,722 Cr. The last four reported quarters add to ₹14,402 Cr.
FY26 revenue came in at ₹13,722 Cr (+15.5% on the year), capping 10 years at 12.1% compound. The latest quarter (Jun 26) printed ₹4,032 Cr, +20.3% year on year — the 6th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +16.3% growth against the decade's 12.1% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +15.9% over the last 4 quarters against +11.4%/yr over the last 8 — accelerating; TTM profit −7.1% vs +4.2%/yr — rolling over.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
J K Cements Ltd's operating margin is 16.0% in the Jun 26 quarter, −5.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 13.0% to 24.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 16.0%, −5.0 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 13.0%–24.0%.
🚨 Why the margin moved: operating margin went −4.4 pp year on year while gross margin went −1.8 pp — the loss came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
J K Cements Ltd earned ₹275 Cr of net profit in the Jun 26 quarter, −15.1% year on year. Full-year FY26 profit was ₹988 Cr. The 10-year compound rate is 33.5%. That is 6.8% of the quarter's revenue. The same quarter a year earlier earned ₹324 Cr.
Jun 26 profit was ₹275 Cr, −15.1% year on year. On the full year, FY26 printed ₹988 Cr (+13.3%), and the 10-year compound rate is 33.5%.
🚨 Why profit moved: revenue contributed +20.3% and the margin −5.0 pp — the quarter was revenue-led despite a thinner margin.
Pace comparison, last four quarters: profit −3.7% vs revenue +16.3%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 218% of J K Cements Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹1,873 Cr of operating cash against ₹988 Cr of profit. After ₹2,458 Cr of capital spending, ₹−585 Cr was left as free cash.
FY26: operating cash of ₹1,873 Cr against reported profit of ₹988 Cr, leaving free cash of ₹−585 Cr after ₹2,458 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 218% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 218%: the cash cycle held roughly steady between FY21 and FY26 — so conversion tracks profitability rather than the cycle.
Router verdict: the bigger cash user is investment — capital spending ran 3.0× depreciation over three years, so the next section's job is to check what that build-out is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
J K Cements Ltd's cash conversion cycle runs 71 days in FY26, down from 73 days in FY21. Capital spending ran ₹5,409 Cr over the last 3 years. At FY26 sales of ₹13,722 Cr each day of that cycle holds about ₹37.6 Cr, so roughly ₹2,669 Cr sits inside the business at any moment.
FY26: debtors at 20 days, inventory at 249 days — roughly 8.2 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 71 days, tighter than FY21's 73.
The full loop: cash goes out to suppliers and production on day 0; stock waits 249 days to sell; customers pay about 20 days after that; and suppliers themselves are paid at 198 days — netting out to the 71-day cycle.
In money terms: at FY26 sales of ₹13,722 Cr, each day of the cycle holds about ₹37.6 Cr — so the 71-day loop keeps roughly ₹2,669 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹5,409 Cr over the last 3 fiscal years against ₹1,827 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹1,055 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
J K Cements Ltd earns a ROCE of 15% in FY26. That is up from a trough of 7% in FY14. Return on invested capital clears the cost of that capital by −2.5 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 7.2% net margin on 0.74× asset turns.
FY26 ROCE is 15%, recovered from a FY14 trough of 7% — the full ladder below shows the fall and the climb, undoctored.
🚨 Why the return is what it is — the wiring (FY26): 7.2% net margin × 0.74× asset turns × 2.63× balance-sheet leverage ≈ 14.0% on equity. Margin does its share; leverage is a meaningful part of the equation.
The capstone test — ROIC − WACC: 9.5% − 12.0% = a −2.5 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
J K Cements Ltd carries total debt of ₹6,206 Cr against shareholder equity of ₹7,090 Cr as of Jun 26, a debt-to-equity of 0.88. On the annual view that ratio went from 0.97 in FY22 to 0.88 in FY26. Read the returns elsewhere on this page with that leverage in mind.
Jun 26: total debt of ₹6,206 Cr against shareholder equity of ₹7,090 Cr — a debt-to-equity of 0.88. On the annual view, debt-to-equity went from 0.97 (FY22) to 0.88 (FY26). Read the returns on this page with that leverage in mind.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Domestic institutions added 1.7 points of J K Cements Ltd over 8 quarters, the biggest move on the register. That takes domestic institutions to 23.7% of the company. Foreign institutions moved −0.9 points over the same window, to 16.9%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Domestic institutions: +1.7 points over 8 quarters to 23.7%; Foreign institutions: −0.9 points over 8 quarters to 16.9%; Promoters: +0.0 points over 8 quarters to 45.7%.
Why the register moved: domestic institutions drove it (+1.7 points), absorbed on the other side by foreign institutions (−0.9 points) — steady accumulation by institutions reading the same numbers this page reads.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
J K Cements Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Star Cement LtdSTARCEMENT | 76.0/100Favorable setup90% evidence | ASLEEP | 29.9/35 Revenue 19.4% · PAT 100% · OPM change 2 pp 88% evidence | 22.4/25 ROCE 16.7% · OPM 27% 100% evidence | 11.3/20 P/E 20.4× · PEG 1.11 100% evidence | 12.4/20 RS sector 13.8% · RS bench -13.2% · 1Y -12.5%1 of 10 weeks ahead 70% evidence |
| Exact sum: 29.9 + 22.4 + 11.3 + 12.4 = 76 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2NCL Industries LtdNCLIND | 69.7/100Favorable setup83% evidence | FADING | 25.3/35 Revenue 1.8% · PAT 100% · OPM change 7 pp 83% evidence | 18.0/25 ROCE 14.5% · OPM 13% 95% evidence | 15.0/20 P/E 6.3× · PEG — 50% evidence | 11.4/20 RS sector 2.1% · RS bench -6.3% · 1Y -18.8%2 of 12 weeks ahead 100% evidence |
| Exact sum: 25.3 + 18 + 15 + 11.4 = 69.7 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 3UltraTech Cement LtdULTRACEMCO | 63.1/100Mixed-positive evidence76% evidence | TURNING | 21.9/35 Revenue 17.2% · PAT 26.7% · OPM change -1 pp 95% evidence | 17.1/25 ROCE 12.7% · OPM 20% 76% evidence | 9.2/20 P/E 40.7× · PEG — 50% evidence | 14.9/20 RS sector 17% · RS bench -1.4% · 1Y -2.8%0 of 10 weeks ahead 70% evidence |
| Exact sum: 21.9 + 17.1 + 9.2 + 14.9 = 63.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Mangalam Cement LtdMANGLMCEM | 62.9/100Mixed-positive evidence96% evidence | FADING | 21.6/35 Revenue 4.6% · PAT 100% · OPM change 0 pp 88% evidence | 11.7/25 ROCE 11% · OPM 11% 100% evidence | 16.0/20 P/E 17.5× · PEG 0.6 100% evidence | 13.6/20 RS sector 24.1% · RS bench 14.9% · 1Y 31.3%5 of 12 weeks ahead 100% evidence |
| Exact sum: 21.6 + 11.7 + 16 + 13.6 = 62.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Rain Industries LtdRAIN | 62.5/100Mixed-positive evidence64% evidence | BREAKING OUT | 22.9/35 Revenue 14.4% · PAT 100% · OPM change 5 pp 62% evidence | 9.4/25 ROCE 8.3% · OPM 15% 76% evidence | 10.2/20 P/E 24.9× · PEG — 15% evidence | 20.0/20 RS sector 61.8% · RS bench 49.7% · 1Y 43.6%12 of 12 weeks ahead 100% evidence |
| Exact sum: 22.9 + 9.4 + 10.2 + 20 = 62.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Orient Cement LtdORIENTCEM | 58.2/100Mixed-positive evidence93% evidence | ASLEEP | 17.6/35 Revenue -12.1% · PAT -19.3% · OPM change 3 pp 100% evidence | 16.9/25 ROCE 16.5% · OPM 24% 100% evidence | 16.1/20 P/E 13.2× · PEG 0.25 65% evidence | 7.6/20 RS sector -12% · RS bench -20.1% · 1Y -45.9%0 of 12 weeks ahead 100% evidence |
| Exact sum: 17.6 + 16.9 + 16.1 + 7.6 = 58.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Dalmia Bharat LtdDALBHARAT | 53.4/100Mixed-positive evidence94% evidence | ASLEEP | 13.0/35 Revenue 7.6% · PAT 0.4% · OPM change -3 pp 100% evidence | 12.8/25 ROCE 7.6% · OPM 21% 100% evidence | 15.3/20 P/E 30.7× · PEG 0.72 100% evidence | 12.3/20 RS sector 12.6% · RS bench -11.9% · 1Y -19.3%0 of 10 weeks ahead 70% evidence |
| Exact sum: 13 + 12.8 + 15.3 + 12.3 = 53.4 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 8Shree Cement LtdSHREECEM | 51.8/100Mixed-positive evidence97% evidence | BREAKING OUT | 15.0/35 Revenue 12.6% · PAT 9.9% · OPM change -5 pp 95% evidence | 13.0/25 ROCE 10.3% · OPM 20% 95% evidence | 9.2/20 P/E 57.7× · PEG 0.96 100% evidence | 14.6/20 RS sector 5.1% · RS bench -3.7% · 1Y -15.8%3 of 12 weeks ahead 100% evidence |
| Exact sum: 15 + 13 + 9.2 + 14.6 = 51.8 · Decision use: Price leads the evidence: RS versus the benchmark is -3.7%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 9JSW Cement LtdJSWCEMENT | 50.8/100Thin evidence · provisional51% evidence | TURNING | 18.6/35 Revenue 12% · PAT -80% · OPM change 5 pp 83% evidence | 12.1/25 ROCE 11.1% · OPM 19% 76% evidence | 10.1/20 P/E 27.8× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y -8.9%5 of 10 weeks ahead 0% evidence |
| Exact sum: 18.6 + 12.1 + 10.1 + 10 = 50.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 10K C P LtdKCP | 49.4/100Mixed-negative evidence77% evidence | ASLEEP | 13.5/35 Revenue 1.9% · PAT 8.7% · OPM change 1 pp 83% evidence | 16.1/25 ROCE 12.2% · OPM 17% 95% evidence | 13.9/20 P/E 10.3× · PEG — 50% evidence | 5.9/20 RS sector -14% · RS bench -9.4% · 1Y -23.5%3 of 11 weeks ahead 70% evidence |
| Exact sum: 13.5 + 16.1 + 13.9 + 5.9 = 49.4 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 11HeidelbergCement India LtdHEIDELBERG | 48.6/100Mixed-negative evidence100% evidence | ASLEEP | 14.5/35 Revenue 6.6% · PAT 2.6% · OPM change -4 pp 100% evidence | 14.7/25 ROCE 14.7% · OPM 11% 100% evidence | 13.7/20 P/E 28.5× · PEG 0.82 100% evidence | 5.7/20 RS sector -5.1% · RS bench -13.3% · 1Y -28.1%0 of 12 weeks ahead 100% evidence |
| Exact sum: 14.5 + 14.7 + 13.7 + 5.7 = 48.6 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 12J K Cements Ltdthis pageJKCEMENT | 48.1/100Mixed-negative evidence94% evidence | TURNING | 11.2/35 Revenue 15.9% · PAT -7.1% · OPM change -5 pp 100% evidence | 16.4/25 ROCE 15.1% · OPM 16% 100% evidence | 8.1/20 P/E 43.1× · PEG 1.46 100% evidence | 12.4/20 RS sector 10.4% · RS bench -7.1% · 1Y -16%0 of 10 weeks ahead 70% evidence |
| Exact sum: 11.2 + 16.4 + 8.1 + 12.4 = 48.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13The Ramco Cements LtdRAMCOCEM | 47.3/100Mixed-negative evidence90% evidence | ASLEEP | 20.6/35 Revenue 6% · PAT 100% · OPM change 1 pp 88% evidence | 13.2/25 ROCE 6.1% · OPM 14% 100% evidence | 1.2/20 P/E 732× · PEG 4.14 100% evidence | 12.3/20 RS sector 11.1% · RS bench -10.1% · 1Y -19.7%0 of 10 weeks ahead 70% evidence |
| Exact sum: 20.6 + 13.2 + 1.2 + 12.3 = 47.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14JK Lakshmi Cement LtdJKLAKSHMI | 47.3/100Mixed-negative evidence65% evidence | ASLEEP | 17.4/35 Revenue 9.2% · PAT 49.6% · OPM change -5 pp 83% evidence | 13.9/25 ROCE 12% · OPM 14% 76% evidence | 10.6/20 P/E 17.6× · PEG — 15% evidence | 5.4/20 RS sector -8.2% · RS bench -23.6% · 1Y -40.3%0 of 10 weeks ahead 70% evidence |
| Exact sum: 17.4 + 13.9 + 10.6 + 5.4 = 47.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Nuvoco Vistas Corporation LtdNUVOCO | 47.1/100Mixed-negative evidence87% evidence | TURNING | 21.0/35 Revenue 9.5% · PAT 100% · OPM change 0 pp 100% evidence | 9.6/25 ROCE 7.1% · OPM 18% 100% evidence | 4.8/20 P/E 29.7× · PEG 8.14 65% evidence | 11.7/20 RS sector 3.6% · RS bench -5% · 1Y -16.5%4 of 10 weeks ahead 70% evidence |
| Exact sum: 21 + 9.6 + 4.8 + 11.7 = 47.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16India Cements LtdINDIACEM | 45.4/100Mixed-negative evidence75% evidence | ASLEEP | 21.3/35 Revenue 7% · PAT 100% · OPM change 7 pp 74% evidence | 3.8/25 ROCE 1.2% · OPM 15% 100% evidence | 5.4/20 P/E 91.4× · PEG — 50% evidence | 14.9/20 RS sector 20% · RS bench -2% · 1Y 10.8%0 of 10 weeks ahead 70% evidence |
| Exact sum: 21.3 + 3.8 + 5.4 + 14.9 = 45.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17Deccan Cements LtdDECCANCE | 43.7/100Mixed-negative evidence70% evidence | ASLEEP | 22.6/35 Revenue 20.6% · PAT 100% · OPM change -3 pp 83% evidence | 7.9/25 ROCE 3.3% · OPM 8.1% 95% evidence | 9.1/20 P/E 43.4× · PEG — 15% evidence | 4.1/20 RS sector -12.9% · RS bench -29.1% · 1Y -47.7%0 of 10 weeks ahead 70% evidence |
| Exact sum: 22.6 + 7.9 + 9.1 + 4.1 = 43.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18ACC LtdACC | 42.5/100Mixed-negative evidence94% evidence | ASLEEP | 9.1/35 Revenue 11.6% · PAT -21.1% · OPM change -5 pp 100% evidence | 9.9/25 ROCE 11.2% · OPM 8% 100% evidence | 16.7/20 P/E 13.4× · PEG 0.92 100% evidence | 6.8/20 RS sector -6.7% · RS bench -16.8% · 1Y -26.5%0 of 10 weeks ahead 70% evidence |
| Exact sum: 9.1 + 9.9 + 16.7 + 6.8 = 42.5 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 19Birla Corporation LtdBIRLACORPN | 41.0/100Mixed-negative evidence94% evidence | ASLEEP | 17.4/35 Revenue 3.9% · PAT 44.6% · OPM change -1 pp 100% evidence | 10.4/25 ROCE 9.8% · OPM 13% 100% evidence | 8.8/20 P/E 12.3× · PEG 3.92 100% evidence | 4.4/20 RS sector -14% · RS bench -17.4% · 1Y -37.4%3 of 9 weeks ahead 70% evidence |
| Exact sum: 17.4 + 10.4 + 8.8 + 4.4 = 41 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 20Sagar Cements LtdSAGCEM | 41.0/100Mixed-negative evidence66% evidence | ASLEEP | 19.5/35 Revenue 13.4% · PAT 79.7% · OPM change -8 pp 95% evidence | 5.1/25 ROCE 2% · OPM 10% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 6.4/20 RS sector -8.1% · RS bench -16.3% · 1Y -28.1%0 of 10 weeks ahead 70% evidence |
| Exact sum: 19.5 + 5.1 + 10 + 6.4 = 41 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 21Ambuja Cements LtdAMBUJACEM | 38.9/100Mixed-negative evidence82% evidence | ASLEEP | 9.4/35 Revenue 7.1% · PAT -5.9% · OPM change -2 pp 95% evidence | 11.0/25 ROCE 5.6% · OPM 17% 76% evidence | 12.6/20 P/E 22.8× · PEG — 50% evidence | 5.9/20 RS sector -7.2% · RS bench -15.1% · 1Y -29.5%0 of 12 weeks ahead 100% evidence |
| Exact sum: 9.4 + 11 + 12.6 + 5.9 = 38.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 22Saurashtra Cement LtdSAURASHCEM | 38.8/100Mixed-negative evidence76% evidence | ASLEEP | 19.7/35 Revenue 8.4% · PAT 87.5% · OPM change -5 pp 83% evidence | 4.8/25 ROCE 2.5% · OPM 6% 95% evidence | 9.5/20 P/E 30.9× · PEG — 15% evidence | 4.8/20 RS sector -16.6% · RS bench -24.6% · 1Y -41.9%0 of 12 weeks ahead 100% evidence |
| Exact sum: 19.7 + 4.8 + 9.5 + 4.8 = 38.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 23Prism Johnson LtdPRSMJOHNSN | 38.2/100Mixed-negative evidence69% evidence | ASLEEP | 12.1/35 Revenue 6.3% · PAT -33.3% · OPM change -2 pp 83% evidence | 5.9/25 ROCE 5.9% · OPM 8% 76% evidence | 8.6/20 P/E — · PEG — 35% evidence | 11.6/20 RS sector 14.3% · RS bench -20.9% · 1Y -32.2%1 of 10 weeks ahead 70% evidence |
| Exact sum: 12.1 + 5.9 + 8.6 + 11.6 = 38.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24BIGBLOC Construction LtdBIGBLOC | 36.7/100Thin evidence · provisional59% evidence | ASLEEP | 15.4/35 Revenue 26.2% · PAT -80% · OPM change -1.6 pp 62% evidence | 5.8/25 ROCE 1.8% · OPM 7.3% 95% evidence | 10.0/20 P/E — · PEG — 0% evidence | 5.5/20 RS sector -9.7% · RS bench -17.9% · 1Y -24.7%3 of 10 weeks ahead 70% evidence |
| Exact sum: 15.4 + 5.8 + 10 + 5.5 = 36.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 25Shree Digvijay Cement Co. LtdSHREDIGCEM | 31.2/100Adverse evidence81% evidence | ASLEEP | 10.8/35 Revenue 19.6% · PAT -35% · OPM change -3.5 pp 95% evidence | 8.2/25 ROCE 6.4% · OPM 8.7% 95% evidence | 6.1/20 P/E 59.4× · PEG — 50% evidence | 6.1/20 RS sector -12.4% · RS bench -10.9% · 1Y -15.8%4 of 10 weeks ahead 70% evidence |
| Exact sum: 10.8 + 8.2 + 6.1 + 6.1 = 31.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 26Shiva Cement LtdSHIVACEM | 36.5/100Thin evidence · provisional42% evidence | 18.1/35 Revenue 19.7% · PAT -47.1% · OPM change 15 pp 40% evidence | 5.4/25 ROCE -3% · OPM 1% 57% evidence | 10.0/20 P/E — · PEG — 0% evidence | 3.0/20 RS sector -27.5% · RS bench -36.4% · 1Y -54.1%0 of 12 weeks ahead to 2026-03-08 70% evidence | |
| Exact sum: 18.1 + 5.4 + 10 + 3 = 36.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is J K Cements Ltd's share price today?
J K Cements Ltd trades at ₹5,444, −18.5% over the past year. The company is valued at ₹42,065 Cr. The stock sits at 30% of its 52-week range of ₹4,815–₹6,947, −1.4% versus its 200-day average. On the tape, the price is in a downtrend, 31 weeks in. — as of 31 July 2026.
What were J K Cements Ltd's latest quarterly results?
J K Cements Ltd reported revenue of ₹4,032 Cr and net profit of ₹275 Cr for the Jun 26 quarter. Revenue rose 20.3% and profit fell 15.1% year on year. Earnings per share were ₹35.91. The operating margin was 16.0%, 5.0 pp lower than a year earlier. — as of 31 July 2026.
What is J K Cements Ltd's revenue?
J K Cements Ltd reported revenue of ₹4,032 Cr in the Jun 26 quarter, +20.3% year on year. For the full FY26 fiscal year, revenue was ₹13,722 Cr (+15.5%). Over the last 10 years revenue compounded at 12.1% a year. — as of 31 July 2026.
What is J K Cements Ltd's profit?
J K Cements Ltd earned ₹275 Cr of net profit in the Jun 26 quarter, −15.1% year on year. Full-year FY26 profit was ₹988 Cr. The operating margin ran 16.0% in the latest quarter. — as of 31 July 2026.
What is J K Cements Ltd's market cap?
J K Cements Ltd's market capitalisation is ₹42,065 Cr at a share price of ₹5,444. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 31 July 2026.
What is J K Cements Ltd's P/E ratio?
J K Cements Ltd trades at a P/E of 43.1×, at the 70th percentile of its own 10-year range, against a long-run median of 36.6×. This is a comparison with the stock's own history, not a value call — as of 31 July 2026.
Does J K Cements Ltd pay a dividend?
Yes — J K Cements Ltd's dividend payout was 16% of profit in FY26, and it recorded a payout in each of its last 13 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 31 July 2026.
Is J K Cements Ltd overvalued?
On its own history, J K Cements Ltd looks expensive against its own history: its P/E of 43.1× sits at the 70th percentile of its 10-year range (long-run median 36.6×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 31 July 2026.
Is J K Cements Ltd growing?
Not right now — J K Cements Ltd's latest numbers are shrinking: latest-quarter revenue +20.3% year on year, profit −15.1%, and the margin −5.0 pp at 16.0%. The 10-year compound rates are 12.1% (revenue) and 33.5% (profit). The earnings engine currently reads: deteriorating — as of 31 July 2026.
How is J K Cements Ltd performing?
J K Cements Ltd is in a downtrend, 31 weeks in. Its latest quarter's revenue rose 20.3% and profit fell 15.1% year on year. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 2 weeks. This describes what the data did, not a rating. — as of 31 July 2026.
What stage is J K Cements Ltd in?
Mixed — no clean majority across the growth curves, ROCE slipping at 13.4% — the per-curve reads carry the story. The read comes from the last 12 quarters of growth (revenue growth +15.9% latest, profit growth −7.1% latest, eps growth −5.5% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 31 July 2026.
Is J K Cements Ltd in an uptrend?
No — the price is in a downtrend (week 31 of stage 4), trading −1.4% versus its 200-day average and at 30% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 31 July 2026.
Is J K Cements Ltd beating the market?
On recent form, yes — J K Cements Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 2 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.4 years the stock moved +833% against the NIFTY 500's +276% — ahead of the index over the full window. — as of 31 July 2026.
Will J K Cements Ltd's share price go up?
This page publishes no price forecast for J K Cements Ltd. What it measures instead: the share price is ₹5,444, the price is in a downtrend 31 weeks in. Its P/E of 43.1× sits at the 70th percentile of its own 10-year range. — as of 31 July 2026.
Who owns J K Cements Ltd?
Promoters hold 45.7% of J K Cements Ltd, foreign institutions 16.9%, domestic institutions 23.7% and the public 13.8% (latest quarter). The biggest move on the register over the last two years: Domestic institutions added 1.7 points over 8 quarters. — as of 31 July 2026.
Does J K Cements Ltd have too much debt?
It is moderate — J K Cements Ltd's debt-to-equity is 0.88, and operating profit covers the interest bill 6×. FY26 borrowings were ₹6,183 Cr against equity of ₹7,037 Cr. Read the returns on this page with that leverage in mind — as of 31 July 2026.
What is J K Cements Ltd's capex?
J K Cements Ltd spent ₹5,409 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹2,458 Cr, with ₹1,055 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 31 July 2026.
What is J K Cements Ltd's cash flow?
J K Cements Ltd generated ₹1,873 Cr of operating cash flow in FY26 and ₹−585 Cr of free cash flow after ₹2,458 Cr of capital spending. Reported profit that year was ₹988 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 31 July 2026.
Is J K Cements Ltd's profit real cash?
Yes — over the last 3 fiscal years, 218% of J K Cements Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹1,873 Cr against reported profit of ₹988 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 31 July 2026.
Where is J K Cements Ltd in its business cycle?
J K Cements Ltd's FY26 operating margin was 17.0%, against a 13-year band of 13.0%–24.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 16.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 31 July 2026.
What could break the J K Cements Ltd story?
The sharpest disagreement: annual EPS moved +15.3% against a −18.5% price move — the market has not yet caught up with the delivery. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 31 July 2026.
Is J K Cements Ltd a stock worth studying right now?
This is not investment advice. The machine read: J K Cements Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: whether the price catches up with earnings that have already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 31 July 2026.